|
1
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garcia R, Bowman TL, Niu G, Yu H, Minton
S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et
al: Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Knüpfer H and Preiss R: Significance of
interleukin-6 (IL-6) in breast cancer (Review). Breast Cancer Res
Treat. 102:129–135. 2007. View Article : Google Scholar
|
|
7
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yue P and Turkson J: Targeting STAT3 in
cancer: How successful are we? Expert Opin Investig Drugs.
18:45–56. 2009. View Article : Google Scholar :
|
|
9
|
Sansone P and Bromberg J: Targeting the
interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol.
30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Azare J, Doane A, Leslie K, Chang Q,
Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M, et
al: Stat3 mediates expression of autotaxin in breast cancer. PLoS
One. 6:e278512011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burke WM, Jin X, Lin HJ, Huang M, Liu R,
Reynolds RK and Lin J: Inhibition of constitutively active Stat3
suppresses growth of human ovarian and breast cancer cells.
Oncogene. 20:7925–7934. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sonnenblick A, Uziely B, Nechushtan H,
Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly
B, et al: Tumor STAT3 tyrosine phosphorylation status, as a
predictor of benefit from adjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat. 138:407–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sonnenblick A, Shriki A, Galun E, Axelrod
JH, Daum H, Rottenberg Y, Hamburger T, Mali B and Peretz T: Tissue
microarray-based study of patients with lymph node-positive breast
cancer shows tyrosine phosphorylation of signal transducer and
activator of transcription 3 (tyrosine705-STAT3) is a marker of
good prognosis. Clin Transl Oncol. 14:232–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walker SR, Nelson EA, Yeh JE, Pinello L,
Yuan GC and Frank DA: STAT5 outcompetes STAT3 to regulate the
expression of the oncogenic transcriptional modulator BCL6. Mol
Cell Biol. 33:2879–2890. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dolled-Filhart M, Camp RL, Kowalski DP,
Smith BL and Rimm DL: Tissue microarray analysis of signal
transducers and activators of transcription 3 (Stat3) and
phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear
localization is associated with a better prognosis. Clin Cancer
Res. 9:594–600. 2003.PubMed/NCBI
|
|
18
|
Walker SR, Xiang M and Frank DA: Distinct
roles of STAT3 and STAT5 in the pathogenesis and targeted therapy
of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014.
View Article : Google Scholar
|
|
19
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Varma S and Simon R: Bias in error
estimation when using cross-validation for model selection. BMC
Bioinformatics. 7:912006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sonnenblick A, Brohée S, Fumagalli D,
Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N,
Loi S, et al: Integrative proteomic and gene expression analysis
identify potential biomarkers for adjuvant trastuzumab resistance:
Analysis from the Fin-her phase III randomized trial. Oncotarget.
6:30306–30316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sonnenblick A, Francis PA, Azim HA Jr, de
Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG,
Ameye L, Anderson M, et al: Final 10-year results of the Breast
International Group 2-98 phase III trial and the role of Ki67 in
predicting benefit of adjuvant docetaxel in patients with oestrogen
receptor positive breast cancer. Eur J Cancer. 51:1481–1489. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Francis P, Crown J, Di Leo A, Buyse M,
Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D,
et al: BIG 02-98 Collaborative Group: Adjuvant chemotherapy with
sequential or concurrent anthracycline and docetaxel: Breast
International Group 02-98 randomized trial. J Natl Cancer Inst.
100:121–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM; Statistics Subcommittee of NCI-EORTC
Working Group on Cancer Diagnostics : REporting recommendations for
tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat.
100:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haibe-Kains B, Desmedt C, Loi S, Culhane
AC, Bontempi G, Quackenbush J and Sotiriou C: A three-gene model to
robustly identify breast cancer molecular subtypes. J Natl Cancer
Inst. 104:311–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al METABRIC Group: The genomic and transcriptomic architecture of
2,000 breast tumours reveals novel subgroups. Nature. 486:346–352.
2012.PubMed/NCBI
|
|
28
|
Dedeurwaerder S, Desmedt C, Calonne E,
Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M,
Deplus R, Luciani J, et al: DNA methylation profiling reveals a
predominant immune component in breast cancers. EMBO Mol Med.
3:726–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tell RW and Horvath CM: Bioinformatic
analysis reveals a pattern of STAT3-associated gene expression
specific to basal-like breast cancers in human tumors. Proc Natl
Acad Sci USA. 111:12787–12792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang SF, Hou MF, Chen FM, Ou-Yang F, Wu
YC, Chai CY and Yeh YT: Prognostic value of protein inhibitor of
activated STAT3 in breast cancer patients receiving hormone
therapy. BMC Cancer. 16:202016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loi S, Haibe-Kains B, Majjaj S, Lallemand
F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans
WF, Bardelli A, et al: PIK3CA mutations associated with gene
signature of low mTORC1 signaling and better outcomes in estrogen
receptor-positive breast cancer. Proc Natl Acad Sci USA.
107:10208–10213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar
|
|
33
|
Sansone P, Ceccarelli C, Berishaj M, Chang
Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, et
al: Self-renewal of CD133(hi) cells by IL6/Notch3 signalling
regulates endocrine resistance in metastatic breast cancer. Nat
Commun. 7:104422016. View Article : Google Scholar : PubMed/NCBI
|
